» Articles » PMID: 36765851

Response to Ovarian Stimulation for Urgent Fertility Preservation Before Gonadotoxic Treatment in -Pathogenic-Variant-Positive Breast Cancer Patients

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2023 Feb 11
PMID 36765851
Authors
Affiliations
Soon will be listed here.
Abstract

pathogenic variants increase the risk of developing early and aggressive breast cancers (BC). For these patients, fertility potential can be directly affected by oncologic treatments. In addition, evidence indicates that -mutated women had a significant reduction in their ovarian reserve. In order to improve their chances of conception after the completion of cancer treatments, fertility preservation should be proposed before the administration of gonadotoxic drugs, ideally by oocyte vitrification after controlled ovarian hyperstimulation (COH). The present investigation aims to assess the ovarian response to COH in -pathogenic-variant carriers diagnosed with BC. Patient characteristics and COH outcomes were compared between -positive ( = 54) and -negative ( = 254) patients. The number of oocytes recovered did not differ between the two groups. However, the oocyte maturation rate and the number of mature oocytes obtained (7 (4.5-11.5) vs. 9 (5-14) oocytes, = 0.05) were significantly lower in the -mutated patients. Although individualized COH protocols should be discussed, -mutated patients would benefit from FP before BC occurs, in order to cope with the potential accelerated decline of their ovarian reserve, optimize the success rate of FP by repeating COH cycles, and to preserve the feasibility of PGT-M by collecting a large amount of eggs.

Citing Articles

Fertility and Pregnancy-Related Issues in Young Carriers With Breast Cancer.

Magaton I, Arecco L, Mariamidze E, Jankovic K, Stana M, Buzzatti G Breast Cancer (Auckl). 2024; 18:11782234241261429.

PMID: 38882447 PMC: 11179469. DOI: 10.1177/11782234241261429.


BRCA Mutations and Fertility Preservation.

Dias Nunes J, Demeestere I, Devos M Int J Mol Sci. 2024; 25(1).

PMID: 38203374 PMC: 10778779. DOI: 10.3390/ijms25010204.

References
1.
Rzepka-Gorska I, Tarnowski B, Chudecka-Glaz A, Gorski B, Zielinska D, Toloczko-Grabarek A . Premature menopause in patients with BRCA1 gene mutation. Breast Cancer Res Treat. 2006; 100(1):59-63. DOI: 10.1007/s10549-006-9220-1. View

2.
Ives A, Saunders C, Bulsara M, Semmens J . Pregnancy after breast cancer: population based study. BMJ. 2006; 334(7586):194. PMC: 1781958. DOI: 10.1136/bmj.39035.667176.55. View

3.
Gunnala V, Fields J, Irani M, DAngelo D, Xu K, Schattman G . BRCA carriers have similar reproductive potential at baseline to noncarriers: comparisons in cancer and cancer-free cohorts undergoing fertility preservation. Fertil Steril. 2018; 111(2):363-371. DOI: 10.1016/j.fertnstert.2018.10.014. View

4.
Gerstl B, Sullivan E, Ives A, Saunders C, Wand H, Anazodo A . Pregnancy Outcomes After a Breast Cancer Diagnosis: A Systematic Review and Meta-analysis. Clin Breast Cancer. 2017; 18(1):e79-e88. DOI: 10.1016/j.clbc.2017.06.016. View

5.
Jazayeri A, Falck J, Lukas C, Bartek J, Smith G, Lukas J . ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat Cell Biol. 2005; 8(1):37-45. DOI: 10.1038/ncb1337. View